The U.S. FDA has released an executive summary statement regarding their position on the association between breast implants and a rare type of lymphoma called anaplastic large cell lymphoma (ALCL). The FDA believes that women with breast implants may have a very small, but increased, risk of developing this disease in the scar capsule that forms around the implant. However, based on available data, it cannot be determined whether the implant itself is the actual cause of the disease. Furthermore, it's unclear as to whether any specific types of implants are more associated with ALCL than other types. In order to study this phenomenon further, the FDA and the American Society of Plastic Surgeons will establish a registry of cases of women with breast implants who have been diagnosed with ALCL. At the current time, the FDA is not recommending prophylactic breast implant removal in patients without symptoms or other abnormalities.
Share your comments here.
0 comments:
Post a Comment